Serum bile acid and unsaturated fatty acid profiles of non-alcoholic fatty liver disease in type 2 diabetic patients

Figure 2 The distribution of bile acids and unsaturated fatty acids distribution among healthy control, type 2 diabetes mellitus without non-alcoholic fatty liver disease, and type 2 diabetes mellitus with non-alcoholic fatty liver disease is examined. A: Clustering analysis is conducted to analyze the levels of serum bile acids (BAs) and unsaturated fatty acid (UFA). Serum levels of BAs and UFAs in three groups. Wilcoxon test (^aP < 0.05); B: Spearman’s correlation analysis between UFAs and clinical indicators in type 2 diabetes mellitus with or without non-alcoholic fatty liver disease (^aP < 0.05, ^bP < 0.01). T2DM: Type 2 diabetes mellitus; HC: Healthy control; NAFLD: Non-alcoholic fatty liver disease; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; C-P: C-peptide; TBIL: Total bilirubin; DBIL: Direct bilirubin; IB: Indirect bilirubin; BMI: Body mass index; TyG: Triglyceride glucose index; TG: Triglyceride; DBP: Diastolic blood pressure; BUN: Blood urea nitrogen; FPG: Fasting plasma glucose; TC: Total cholesterol; LDL-C: Low-density lipoprotein cholesterol; UA: Uric acid; SCR: Serum creatinine; HDL-C: High-density lipoprotein cholesterol; SBP: Systolic blood pressure; HbA1c: Glycosylated hemoglobin; CDCA: Chenodeoxycholic acid; TLCA: Taurolithocholicacid; GDCA: Glycodeoxycholic acid; UDCA: Ursodeoxycholic acid; TDCA: Taurodeoxycholic acid.